Thymagen (also called thymogen; dipeptide Glu-Trp, EW) is a synthetic peptide analog derived from thymic extracts and regarded in peptide bioregulator research for its putative immunoregulatory and ...

Recent advancements in cancer vaccine development have demonstrated their potential for precise tumor targeting through ...

Single-ascending dose portion of study has successfully completed 2.5 and 7 mg / kg levelsDose dependent immunosuppressive ...

This study developed a pH-responsive nanovaccine (Lyc-OVA) based on Lycium barbarum-derived carbon dots (Lyc-CDs) synthesized ...

Activation of certain memory B cells may be driving systemic lupus erythematosus incidence in individuals who had ...

Engineered dendritic cells capture tumor EVs, enhancing antigen presentation and T cell activation to boost cancer immunotherapy in preclinical models.

Background: Serum amyloid A (SAA), an acute-phase pro-inflammatory protein, is overexpressed in several cancers and is involved in shaping pro-tumor responses. We have previously reported that lung ...

Detailed price information for Immix Biopharma Inc (IMMX-Q) from The Globe and Mail including charting and trades.

METiS TechBio ("METiS") today announced that two of its oncology pipeline candidates, MTS-105 and MTS-107, have been published in leading international peer-reviewed journals, Nature Communications ...

Neoantigen vaccines are at the forefront of cancer research, driving personalized immunotherapy and improving outcomes ...

Cancer immunotherapy has transformed cancer treatment, yet many patients experience limited or short-lived responses due to immune evasion, tumor heterogeneity, and immune-related adverse events.